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The purpose of this study was to formulate rebamipide nanocrystal tablets (REB-NTs) by
wet-milling technique to enhance its dissolution rate and oral bioavailability. The formu-
lation and preparation technology were screened by single factor tests with particle size
and distribution as indicators. Rebamipide nanocrystals (REB-NSs) was then achieved by
freeze-dry from the prepared nanosuspensions which were characterized by differential
scanning calorimetry (DSC) and x-ray powder diffraction (XRD), while the vitro dissolution
and the plasma drug concentration of the nanocrystal tablets were investigated. The re-
sults indicated that the prepared nanosuspensions got an average particle size of 286 nm,
PI of 0.173 and the average Zeta potential of 18.2 mv. The average particle size of obtained
REB-NSs’ redispersibility was 278 nm, and the crystalline of REB-NSs was the same as the
rebamipide bulk drug as shown by DSC and XRD. The drug dissolution rate of self-made
nanocrystal tablets in different dissolutions was slightly faster than that from the refer-
ence tablets, REB-MTs (Mucosta®), while the Cmax and AUC0e24 of REB-NTs were 1 and 1.57
times higher than that of REB-MTs, which means the nanotechnology could significantly
improve the oral bioavailability of rebamipide.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rebamipide (REB) is a quinolone derivative drug, which is used
to treat gastric and gastric mucosal lesions in acute gastritis
and acute exacerbation of chronic gastritis [1,2]. Because of its
low solubility and low permeability, the bioavailability of
rebamipide is under 10% in humans, thus rebamipide is
classified into biopharmaceutics classification system
IV(BCSIV) [3]. Referred to solubility test of the literature [3],tical University, No. 103,
u).
g Pharmaceutical Univer
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ns.org/licenses/by-nc-ndRBM was nearly indissolvable not only in polar but also in
non-polar solvents. Shi YJ [4] prepared rebamipide nano-
suspensions and improved its oral bioavailability. Nano-
suspensions, also called nanocrystals, was regarded as an
alternative and promising approach to settle these problems.
It is a type of submicron colloidal dispersion system, wherein
drug particles are distributed in water with a surfactant or
polymer as a stabilizer through a self-assembly or broken
preparation technology [5e7]. As a potential technique,Wenhua Road, Shenyang 110016, China. Tel./fax: þ86 24 23986293.
sity.
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increase the solubility of poorly soluble drugs lately [8]. The
solubility was improved by reducing the drug particle size into
the nano (sub-micron) range in the usage of nanocrystal
technique. In this way, saturation solubility (Cs) was
increased, then dissolution rate (dc/dt) and bioavailability (F%)
related to the formulation of poorly soluble drugs could be
enhanced. At present, both top-down and bottom-upmethods
are widely used in the field of research in the new dosage
form. The top-down wet milling technique can provide highly
nanocrystalline with improved physical stability compared
with the bottom-up micro-fluidic precipitation method [9,10].
In this study, we adopt wet-millingmethod to prepare REB-
NTs. The goal of this research was to develop a formulation of
REB-NTs for oral administration and to investigate the relative
bioavailability in vivo using a rat model. A commercial REB
product, Mucosta®, was used as a control for the dissolution
and in vivo assay.2. Materials and methods
2.1. Materials
REBwas synthesized and donated by Department ofMedicinal
Chemistry, Shenyang Pharmaceutical University. PVP K30,
HPMC K4M and HPMC E5 were supplied by Anhui Shanhe
Pharmaceutic Adjuvant Co. Ltd, Pluronic F68 (poloxamer 188)
was obtained from BASF (Germany). The commercial reba-
mipide tablets (brand name Mucosta®, 100 mg/pill, Zhejiang
dazhong zhiyao Co. Ltd, Batch No.121216R) as the reference
product. All the other chemicals were of analytical grade or
chromatographic grade.
Male SD rats weighing about 220 g (200e240 g) were
obtained from the Experiment animal center of Shenyang
Pharmaceutical University (Shenyang, China). Animal exper-
iments were performed in compliance with the Guide for the
Care and Use of Laboratory Animals and the declaration
announced by the Animal Ethics Committee of Shenyang
Pharmaceutical University.2.2. Methods
2.2.1. Solubility determination of REB
The solubilities of REB in different pH aqueous solutions were
determined. Excess Rebamipide was added to the buffer so-
lutions, and all themixtureswere shaken in an air bath shaker
for 72 h at 37 C, then centrifuged at 3500 rpm for 10 min to
remove supernatants which were appropriate diluted with
the same buffer solutions before being analyzed by HPLC.
HPLC condition: HITACHI 2000 HPLC system (HITACHI Pump
L-2130, HITACHI UV Detector L-2420, HITACHI AutoSampler
L-2200, Japan, Hitachi) with an Welch Ultimate®AQ-C18
(150 mm  4.6 mm, 5 mm) (Welch, Shanghai, China); the mo-
bile phase was acetonitrile-phosphate buffer solutionmixture
(17:83, v/v); the column temperature was maintained at 35 C
and the wavelength was 254 nm; 20 ml of sample was injected
into HPLC system with the flow rate of 1 ml/min. Each sample
was analyzed in triplicate.2.2.2. Preparation of REB-NTs
The nanosuspensions were prepared by a beadmill (ESW-750,
Shanghai Yile electromechanical Co. Ltd., Shanghai) using
wet-milling technique. Different types of stabilizers (F68,
HPMC K4M, HPMC E5, PVP K30) were dissolved in 100ml water
with the concentrations of 5% (w/v), then 20 g of drug powder
was dispersed in the aqueous stabilizer solution. The obtained
suspensions were added in the milling bowl where the parti-
cles were broken into pieces by milling pearls (zirconium
oxide, diameter 0.2 mm). The milling time was 30 min. In
order to improve the stability of REB nanosuspensions, the
obtained nanosuspensions were freeze-dried using FDU-1100
(EYELA, Tokyo Rikakikai Co. Ltd, Japan). A variety of freeze
drying protectors including glucose, maltose, lactose, sucrose
andmannitol were investigated with the concentrations of 3%
(w/v). The freeze-drying process was as follows: first, 1 ml of
the nanosuspensions were poured into a glass bottle with the
diameter of 20 mm and placed at 80 C for 12 h, and subse-
quently lyophilized at a temperature of 40 C for 3 h, fol-
lowed by a secondary drying phase of 16 h at 20 C, and then
about 1 h at 10 C. The obtained freeze-dried powders were
mixed with suitable adjuvants, then compressed into tablets
by wet granulation.
2.2.3. Particle size and zeta potential
A Zetasizer Nano (Malvern Instruments, UK) was used to
determine the mean particle size (z-average) and the poly-
dispersity index (PI) which was regarded as a measurement of
the width of size distribution. Before the measurement, the
samplesweredilutedwithdistilledwater toasuitablescattering
intensity and re-dispersed by handshaking, then each sample
was determined in triplicate with 13 runs and 60 s duration in
each measurement at 25 C. Because of its ability of expressing
the electric charge at the surface of the particles, the zeta po-
tential (ZP)was commonly usedasameasurement of indicating
thephysicalstabilityofcolloidal systems. Inthis study, thesame
Malvern Zetasizer was used to measure the ZP values by deter-
miningtheparticleelectrophoreticmobilityof theparticles inan
electrical field, which was transformed to the zeta potential.
2.2.4. Differential scanning calorimetry (DSC)
DSC analysis was carried out using a differential scanning
calorimeter (DSC 1 STARe, Mettler-Tolelo International Inc,
Scotland). Samples (REB bulk drug, blank excipients, physical
mixtures and REB-NSs) of about 3mgwereweighed accurately
and put in standard aluminum pans and sealed with a lid. The
phase transition of sample was analyzed by differential
scanning calorimetry at a heating rate of 10 C/min from 5 C
to 350 C with a nitrogen purge of 20 ml/min.
2.2.5. X-ray powder diffraction (XRD)
Samples (REBbulkdrug,blankexcipients,physicalmixturesand
REB-NSs) were evaluated with X-ray diffractometer (D/MAX-
2400, Rigaku, Japan). The diffraction patternwas performed in a
stepscanmodeloverananglearrangeof3 <2q<45,withastep
size of 0.02.
2.2.6. Dissolution tests for REB-NTs
Dissolution tests were performed according to Apparatus II
(paddle)method of JP X IV using ZRS-8G (Tianjin Tianda Tianfa
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 2 3e2 2 9 225Technology Co. Ltd., Tianjin, China). Water with different
concentration of SDS, pH 5.0 with different concentration of
SDS, pH 1.2 HCl solution with 0.5% Tween 80, pH 6.0 (1/ 4)
phosphates-citric acid buffer solution and pH 6.8 PBS were
used as the dissolution media respectively. The dissolution
tests were carried out at the temperature of 37 C in 900 ml
dissolutionmedia, and the rotary speed of the paddles was set
at 50 rpm. REB-NTs and REB-MTs were placed in the dissolu-
tionmedia, sampleswerewithdrawn at 5, 10, 15, 20, 30, 45 and
60 min, and immediately passed through a 0.45 mm millipore
filter. The initial filtrate was discarded and the continuous
filtrates was appropriately diluted. The mixtures were further
analyzed by UV spectrophotometer (UV-1801, Beijing Rray-
leigh Analytical Instrument company, China) at 326 nm.
2.2.7. Drug administration and blood plasma collection
The pharmacokinetics of the test preparations (REB-NTs) were
compared with that of a reference formulation of Mucosta®
tablets (REB-MTs). Test and reference samples were prepared
by grinding with a pestle and mortar, then the powders were
sieved through a 100-mesh sieve and suspended in a solution
of sodium carboxymethyl cellulose 0.5%. Twelve Male SD rats
were randomly assigned into two groups, then fasted for 12 h
before drug administration and food was reoffered 4 h after
dosing. The two solutions were administered orally to two
groups of rats respectively at a dose of 10 mg/kg 200 ml blood
samples were withdrawn from the posterior vena orbitalis at
0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 h postdosing
and placed into heparinized tubes. Blood samples were
instantly centrifuged at 13,000 rpm for 10 min. Plasma was
separated from samples and stored at 20 C until the time of
analysis.
2.2.8. Sample preparation
Before analysis, the plasma samples were thawed at ambient
temperature. 100 ml plasma was added to a test-tube, then
50 ml internal standard solution and 50 ml water: methanol
(50:50, v/v) were pipetted into the same tube, respectively.
After a thorough vortex mixing for 5 min, mixtures were
precipitated with 200 ml methanol, vortex-mixed vigorously
for 5 min, and then the tube was centrifuged at 13,000 rpm for
10 min. Its supernatants (10 ml) were injected into the LC-MS/
MS system.
2.2.9. Drug concentration analysis in vivo
The LC-MS-MS method was set up to determine the drug
concentrations in plasma. The assay was performed using
Waters ACQUITY UPLC™/Tandem Quadrupole Detector sys-
tem (Waters Crop., Milford, MA). Liquid chromatographic
separations were carried out by using a ACQUITY UPLC™ BEH
C18 column (50 mm  2.1 mm, 1.7 mm, Waters Corp, Milford,
MA, USA). The column and autosampler tray temperature
were maintained at 35 and 4 C, respectively. The mobile
phase consisting of methanol (A) and water containing 0.2%
formic acid (B) was used at a flow rate 0.2 ml/min. The
gradient elution was from 45% A to 60% A within 0.4 min and
then held for 0.8 min, from 1.2 to 1.3 min, the percentage of A
was increased to 70% and maintained about 1 min, then
reduced to the initial condition within 0.2 min and balanced
for 0.5 min. The total running time was 3 min and the sampleinjection volume was set at 10 ml. The UPLC system was
connected with the mass spectrometer through an ESI inter-
face and was operated in the positive ion detection mode.
Nitrogen used for desolvation was 650 l h1, cone gas was set
at 50 l h1. The capillary voltage was set at 2.85 KV, Source
temperature 120 C, desolvation temperature 350 C. The
compounds (REB and IS) were analyzed using multiple reac-
tion monitoring (MRM) mode at m/z 371.3 / 216.3 (cone
voltages ¼ 28 v, collision energy ¼ 25 v) for REB, and m/z
278.3/ 58.04 (cone voltages¼ 12 v, collision energy¼ 17 v) for
venlafaxine (IS). Data acquisition was processed with Mas-
slynx 4.1 software.
The calibration curves were linear (r2  0.99) over the
concentration range of 40e4000 ng/ml with the lower limit of
quantification (LLOQ) of 40 ng/ml with relative standard de-
viation (R.S.D.) lower than 10%. The extraction recoveries of
REB were 94.8, 89.1, and 93.2% at the concentrations of 80, 500
and 3200 ng/ml, respectively. Mean recovery for the IS was
86.8%. The intra-day precisions, calculated from quality con-
trol (QC) samples at three concentration levels of 80, 500, and
3200 ng/ml, was found to be below 6%. The inter-day pre-
cisions as determined from QC sampling was within 7%.
2.2.10. Statistical analysis
Pharmacokinetic analysis was carried out by means of a
model independent approach. The maximum plasma con-
centration of REB (Cmax) and corresponding peak time (Tmax)
were obtained by observation of the individual drug plasma
concentration-time profiles. The area under the curve to the
last data point (AUC0et) was calculated by the trapezoidal rule.
The slope of the terminal four points in plasma concentration-
time curve was conducted as the elimination rate constant
(Ke). The elimination half-life (t1/2) of the preparation was
calculated by 0.693/Ke. The relative bioavailability (F%) was
calculated as follows:
F% ¼ AUC0tðtestÞ=AUC0tðreferenceÞ  100%
3. Results and discussion
3.1. Solubility determination of REB
As a water insoluble compound, it was necessary to investi-
gate the determination of the solubility of REB, which was
regarded as the background of selecting the dissolution me-
dium. Table 1 showed the saturation solubility of REB bulk
drug in different solution, includingmethanol, alcohol, pH 1.0
hydrochloric acid buffer solution, pH 4.5 acetate buffer solu-
tion, pH 5.0, 5.5, 5.8, 6.0, 6.8, 7.4 phosphates buffer solution
and pH 6.0 (1/ 4) phosphate-citric acid buffer solution. The
saturation solubility of REB in 0.1 mol/l HCl was extremely
low being only 0.33 mg/ml. The solubility was increased with
the increase of pH value. In this study, the saturation solu-
bility of REB in water was 25 mg/ml, while the notable
enhancement of the solubility was found to be in the pH value
of 7.4 to be 376 mg/ml. And the results indicated that the sink
condition for 100 mg tablets could be achieved in the disso-
lution medium pH 6.0 (1 / 4) phosphates-citric acid buffer
solution.
Fig. 2 e The effect of the type of stabilizer on the particle
size distribution.
Table 1 e Saturation solubility of REB in different pH
media at 25 C.
Media Solubility (mg/ml)
pH 1.0 HCl 0.00033
pH 4.5 0.013
water 0.025
pH 5.0 0.022
pH 5.5 0.061
pH 5.8 0.115
pH 6.0 0.199
pH 6.0 (1/ 4) 0.417
pH 6.8 1.215
pH 7.4 3.760
Methanol 0.770
Alcohol 0.322
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In our research, milling-time was investigated in the process
of wet-milling. While the same stabilizer concentration
(5% stabilizer, w/v) was added,mean particle sizes (Z-Average)
of REB nanosuspensions but different milling times were
displayed in Fig. 1. With increasing milling times, the mean
particle of REB was reduced. After 5 min of milling, the mean
particle size was decreased obviously to be about 600 nm.
However, when the milling time exceeded 30 min, the mean
size of the particle was changed slightly.
3.3. Choice of the stabilizer and its concentration
Four stabilizers including F68, HPMC K4M, HPMC E5 and PVP
K30 were chosen to be investigated. As can be seen in Figs. 2
and 3, with constant milling time of 30 min, the mean parti-
cle sizes and polydispersity index (PI) were influenced not only
by different stabilizers but also by the concentrations of sta-
bilizer. The mean size of REB particles decreased to 326 nm
stabilized by F68, 358 nm stabilized by PVP K30, 313 nm sta-
bilized by HPMC K4M and 284 nm stabilized by HPMC E5
(Fig. 2). HPMC E5 was themost effective stabilizer for REB with
a lower PI of 0.178, followed by HPMC K4M. With differentFig. 1 e Effect of the milling time on the mean particle size
of the suspension.concentration levels of HPMC E5 as the stabilizer, the dispar-
ities of mean particle size and PI of drug particles were re-
flected in Fig. 3. Nanosuspensions prepared using 2% and 5%
of HPMC E5 contributed the average diameter of 363 nm and
284 nm, correspondingly. As increasing the concentration of
the stabilizer, i.e., 8% and 10%, the particle size remained
almost the same.3.4. Determination of particle size and zeta potential
Themeasurement of themean particle size and zeta potential
of suspensions represented a good estimation about formu-
lation stability [11]. The mean particle size and zeta potential
of REB nanosuspensions were 286 nm and 18 mV, respec-
tively. Even the existence of electrostatic stabilization, it could
maintain a short time stability merely [12,13]. In order to
improve its' long-term stability, lyophilization was adopt to
convert nanosuspensions into powders for furthermore
investigation, i.e., compressed into nanocrystal tablets. REB-
NSs freeze-dried in the presence of cryoprotectant possessed
a good redispersibility with amean particle size of 278 nm and
PI of 0.180, a much smaller size of 344 nm (PI ¼ 0.280) without
cryoprotectant.Fig. 3 e The effect of the amount of stabilizer on the particle
size distribution.
Fig. 5 e XRD of REB bulk drug (A), freeze-dried powder (B),
physical mixture of freeze-dried powder (C) and blank
excipients of freeze-dried powder (D).
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The REB bulk drug, freeze-dried powder, physical mixture of
freeze-dried powder, and blank excipients of freeze-dried
powder of all the materials were analyzed by DSC and XRD
(Figs. 4 and 5). As shown in Fig. 4, the DSC curve of REB bulk
drug exhibited a single sharp endothermic melting peak at
305 C, in accordancewith literature [3], the endothermic peak
of blank excipients demonstrated at the temperature of 80 and
153 C, respectively. In physical mixtures, the same endo-
thermic peaks could be checked out simultaneously. The REB-
NSs showed a slightly shifted endothermic melting peak
(300 C) compared to the bulk REB. However, the melting point
of the bulk REB was higher than that of the REB-NSs and this
phenomenon could be explain as particle size reduction
[14,15]. It could be deduced that there was no substantial
crystalline change. As shown in Fig. 5, it was supposed that
almost no crystalline changes was detected in REB-NSs,
because of the peaks in XRD of REB-NSs were in accordance
with that in the physical mixture. In conclusion, the charac-
teristic results confirmed that the crystalline state of REB had
been unchanged after wet-milling and freeze-dry.
3.6. Dissolution tests
The in vitro drug dissolution test was carried out with
different dissolution media. As mentioned in 3.1, pH 6.0
(1/ 4) phosphates-citric acid buffer solution was defined as
sink condition for 900ml dissolutionmedium and a fixed dose
of 100 mg REB, while the other media referred in the research
except pH 6.8 phosphate buffer solution turned out to be
oversaturation dissolution media. Almost 100% of the drug in
REB-NTs was released within 45 min in pH 6.0 (1 / 4)
phosphates-citric acid buffer solution and pH 6.8 media,
whereas the dissolution rate of REB-MTswas slightly slower at
the first 20 min. The dissolution amount from REB-NTs in the
oversaturation dissolutionmedia weremuch higher than that
from REB-MTs, especially in water with different concentra-
tion of SDS, in which the released drug from REB-NTs was
about 1 time greater than that of REB-MTs (Fig. 6).Fig. 4 e DSC thermograms of REB bulk drug (A), freeze-
dried powder (B), physical mixture of freeze-dried powder
(C) and blank excipients of freeze-dried powder (D).According to the Noyes-Whitney and OstwaldeFreund-
lich equations, both particle size reduction and an augmen-
tation of the surface area with the enhancement of
saturation solubility further resulted in an increase in the
dissolution velocity [16,17]. It was worth noting here that,
within the first 5 min, nearly no distinction was observed in
the dissolution rate of two tablets in the same supersatura-
tionmedia. That was conjectured that because the process of
disintegration of the tablets cost some time to break into
pieces, then drug dissolved from the fragments, and directly
resulted in the lag-time phenomenon of drug concentration
in those media.3.7. In vivo evaluation
In our research, the concentrations of REB in samples ob-
tained fromplasma of SD rats were determined by themethod
mentioned above. The UPLC-MS/MS method and extraction
process were validated. The mean concentration-time curves
for the two types of REB tablets are shown in Fig. 7. The
pharmacokinetic parameters including maximum peak con-
centration of the drug in plasma (Cmax), the time to reach
maximum concentration (tmax), half life (t1/2), area under the
curve (AUC) and elimination rate constant (ke) for both tablets
were shown in Table 2. The higher Cmax values of REB-NTs
suggested that more drug was absorbed into blood after
rapid dissolution in the gastrointestinal tract. The Cmax and
AUC0e24 values of REB-NTs were approximately 1 and 1.57
times higher than that of REB-MTs, respectively. The relative
bioavailability of REB nanocrystal tablets was 256.8%, which
means the nanotechnology could significantly improve the
bioavailability of rebamipide. The effects could be interpreted
that the higher drug concentration indicated drug molecules
could be absorbed rapidly from gastrointestinal wall due to
the notably elevated dissolution rate by decreasing particle
size [18].
Fig. 6 e Effect of two types of tablets on dissolution in different dissolutionmedium (n¼ 3). A 0.01%SDS-water; B 0.01%-SDS-
pH 5.0; C 0.05%SDS-water; D 0.05%-SDS-pH 5.0; E 0.1%-SDS-water; F 0.1%-SDS-pH 5.0; G pH 6.0 (1/ 4); H pH 6.8; I 0.5%-
Tween-pH 1.2.
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Fig. 7 e Average REB plasma concentration-time curves of
REB-NTs and REB-MTs (Each point represents the
mean ± SD of 6 rats).
Table 2 e Pharmacokinetic parameters following oral
administration of REB-NTs and REB-MTs in a single dose
of 10 mg/kg in SD rats (data were expressed as
mean ± SD, n ¼ 6).
Pharmacokinetic parameters REB-NTs REB-MTs
Cmax (ng/ml) 543.4 ± 150.5 281.5 ± 66.1
Tmax (h) 1.67 ± 0.41 1.08 ± 1.34
t1/2 (h) 3.82 ± 0.52 3.34 ± 0.73
k (h1) 0.18 ± 0.03 0.22 ± 0.07
AUC0e24 (ng$min/ml) 2622.3 ± 462.8 1187.4 ± 411.8
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The purpose of this study was to formulate and characterize
REB-NTs to enhance the dissolution rate and oral bioavail-
ability of this drug. The preparation method of nano-
suspensions was supplied using wet-milling technique. HPMC
E5 was considered to be an optimal stabilizer for obtaining the
minimus particle size and PI. The X-ray powder diffraction
(XRD) and differential scanning calorimetry (DSC) analysis
indicated that no substantial crystalline change was detected
in the nanocrystals compared with REB bulk drug. The in vivo
study suggested that the Cmax and AUC0-24 values of REB-NTs
in SD rats were approximately 1-fold and 1.57-fold higher than
that of REB-MTs, respectively. In conclusion, nanocrystal drug
delivery system was an effective strategy in enhancing the
oral bioavailability of the insoluble drugs.r e f e r e n c e s
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